Novo Nordisk Goes ‘Full-Speed Ahead’ Towards Once-Weekly Basal Insulin
Readouts to all six ONWARDS trials to come in 2022, Development Head Says
Novo Nordisk’s once-weekly injected basal insulin icodec could be a boon to the many people with type 2 diabetes who are reluctant to start on insulin therapy due to the need for daily injections, the Danish group’s head of development tells Scrip.
